New in vivo gene editing biotech blossoms from CRISPR pioneer Jennifer Doudna’s lab with $82M
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics…